Industry experts, entrepreneurs, investors, clinical operations professionals, regulatory affairs experts, data scientists, and technology innovators from the pharma industry, are invited to attend the 20th BioPharma Clinical Trials Nexus Conference being held on May 8-9, 2024, in Sheraton Mission Valley San Diego Hotel, San Diego.

The exclusive BioPharma Clinical Trials Nexus, accessible only by invitation, brings together prominent solution providers and clinical trial executives under one roof. As a prestigious two-day event, the conference content is carefully curated for two days of collaboration and immersive learning. This mega networking conference provides attendees with ample opportunities to meet industry pioneers and share their vision.

The topics on the agenda include:

• Navigating Regulatory Challenges in Global Clinical Trials
• Leveraging Artificial Intelligence and Machine Learning in Clinical Trials
• Accelerating Patient-Centric Drug Development
• Harnessing Real-World Data for Evidence Generation
• Optimizing Site Selection and Patient Recruitment Strategies
• Implementing Digital Health Technologies for Remote Monitoring
• Enhancing Diversity and Inclusion in Clinical Research

Building Meaningful Business Relations

The highly anticipated 20th BioPharma Clinical Trials Nexus Conference is renowned for addressing the key challenges faced by the clinical trial industry. It serves as an epitome of excellence and advancements in clinical research. Experts will share advanced business strategies and industry innovations to help professionals stay ahead of the curve.

The 20th BioPharma Clinical Trials Nexus Conference serves as a hub for life sciences innovation, uniting prominent suppliers with advanced clinical trial executives. It will feature industry experts and thought leaders to explore evolving trends that will innovate the clinical trial ecosystem. Attendees can join panel discussions and keynote presentations to gain actionable insights and stay abreast of industry developments.

To learn more, please visit https://ibn.fm/aFIKO

Entrepreneurs, influencers, advocates, patients, investors, service providers, educators, and consumers of the cannabis spectrum, are all invited to attend the first-ever Cannabis Convention of Maryland that focuses on networking, learning, and discovering new cannabis products and services for the greater Maryland community.

NECANN organizes the foremost cannabis events, with a robust platform for cannabis enthusiasts to connect with industry experts and peers, presenting critical knowledge to expand businesses. NECANN has offered growth opportunities to the local communities throughout the northeast and beyond since 2014. It has boosted the cannabis economy by creating a hub of resources and communication available to the local markets.

Traders and service providers from the Maryland community can exhibit their products and services to gain visibility among the investors and key business experts of the cannabis industry. They can showcase their unique products at the exhibitor booths and pitch their businesses and products directly to investors, consumers, and others. Newbies quickly expand their knowledge base by connecting with industry veterans visiting the convention.

The attendees will witness an impressive lineup of powerful speakers and industry leaders. They will share useful insights about the current industry trends and important issues of the cannabis trade. These industry veterans will discuss engaging topics that impact & concern the cannabis community in Maryland.

The dedicated NECANN team works hard to give the attendees a wholesome and productive experience of networking, with meaningful exchanges among the attendees. Available information includes myriad topics covering every aspect of the cannabis industry, ranging from inventory, legal issues, packaging, insurance, regulations, security and testing, to cultivation, marketing, and more.

The Maryland Cannabis Convention & Expo promises to be a one-of-a-kind experience, where the cannabis community explores, discovers, and exchanges must-know information about the business of cannabis.

To know more, please visit https://ibn.fm/V1f1e

• D-Wave will release its financial results for the fourth quarter and fiscal year 2023 before market open on Thursday, March 28, 2024
• D-Wave will host a conference call on March 28, 2024, at 8:00 a.m. (Eastern Time) to address the company’s financial performance and strategic outlook
• CEO Alan Baratz and CFO John Markovich will participate in the conference call discussion

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, recently announced the scheduled release of its financial results for the fourth quarter and fiscal year 2023, which concluded on December 31, 2023. The release is set for Thursday, March 28, before the market opens. Interested parties can access the press release via the D-Wave Investor Relations website: https://ir.dwavesys.com/.

In conjunction with the disclosure, D-Wave will host a conference call on March 28, 2024, at 8:00 a.m. (Eastern Time) to explain the company’s financial performance and strategic outlook. The live dial-in numbers for the call are 1-800-267-6316 (domestic) or 1-203-518-9783 (international). Chief Executive Officer Dr. Alan Baratz and Chief Financial Officer John Markovich will participate in the discussion.

D-Wave is at the forefront of driving commercial adoption of practical quantum computing solutions, utilized by a number of the world’s most advanced organizations. Customers that have used D-Wave’s technology include Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory. The company also possesses a robust intellectual property portfolio, comprising more than 200 issued U.S. patents and over 240 scientific papers published, including in high-impact journals such as Science and Nature.

D-Wave offers a range of innovative solutions to facilitate quantum computing adoption and application development:

The Leap(TM) real-time quantum cloud service, available in 39 countries around the world, offers developers access to state-of-the-art quantum computers and a quantum-classical hybrid solver service that can handle problems with up to one million variables.

Launch(TM) offers customers a multi-faceted approach to identifying and building in-production quantum hybrid applications. D-Wave’s professional services team works with customers to help identify which problems would be most impacted by quantum solutions, develop quantum proofs-of-concept, pilot hybrid quantum applications, and deploy those applications into production.

The Ocean(TM) software development kit (“SDK”), offers a full suite of open-source programming tools, available on the D-Wave GitHub repository and within the Leap quantum cloud service. The Ocean SDK simplifies the process of building quantum hybrid applications while reducing associated time and cost.

D-Wave is focused on delivering quantum solutions for computationally complex problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, financial modeling, and more. As the only company providing annealing quantum computers, the company is unlocking commercial use cases in optimization today. Its customer success stories demonstrate how its quantum solutions are helping drive tangible ROI for businesses now.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding continued commercial adoption of practical quantum computing solutions and D-Wave’s future ability to deliver quantum solutions for computationally complex problems. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against D-Wave; risks related to the performance of its business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that its securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. the company undertakes no duty to update this information unless required by law.

• The global solar energy market is forecasted by Fortune Business Insights to rise from $3.33 billion in 2022 to over $20 billion by 2030
• Turbo Energy S.A. will be part of the explosive growth, as tech-infused photovoltaics become instrumental in more efficient use of solar energy
• Turbo Energy S.A. is a leader in the residential markets in Spain, offering a complete lineup of Li-ion batteries, inverters, software, and their turnkey product, Sunbox

The world is facing a critical juncture. Our dependence on fossil fuels has demonstrably contributed to climate change, necessitating a global shift towards cleaner, more sustainable energy sources. Solar energy, harnessed through photovoltaic (“PV”) technology, offers a promising solution. However, to truly unlock its potential and pave the way for a more sustainable future, advancements in technology are crucial.

The answer resides in the exciting world of tech-infused photovoltaics, the path towards widespread solar harvesting and energy management, and the potential role Turbo Energy (NASDAQ: TURB) can play in this revolution.

The Rise of Tech-Infused Photovoltaics:

Traditional PV panels have served as the workhorses of solar energy generation. However, limitations exist and have become increasingly clear in recent years. Efficiency rates, the percentage of sunlight converted to electricity, are often capped, and energy production can fluctuate based on weather conditions. Here’s where technology steps in.

Scientists are constantly innovating in materials science, creating next-generation products. Perovskite solar cells, for example, hold immense promise with the potential to surpass the efficiency limits of traditional silicon-based panels. Artificial Intelligence (“AI”) has percolated into nearly all walks of life today, including photovoltaics. AI, which Turbo Energy leverages, can optimize panel use, manage energy production and storage more efficiently.

AI dovetails with IoT (Internet of Things), where sensors in solar panels can provide real-time data on performance, enabling proactive maintenance and maximizing output. Lastly, integrating solar energy into “smart grids” allows for a more dynamic and interconnected energy ecosystem, enabling efficient distribution and balancing of power demands.

Cumulatively, these technological advancements are transforming photovoltaics, generating more electricity from the same amount of sunlight, and subsequently using it more efficiently. They will be a driving force in a global solar energy market forecast by Fortune Business Insights to rise from $3.33 billion in 2022 to over $20 billion by 2030.

TURB: the Road to Sustainable Energy

Turbo Energy S.A., which just came public in September, designs, develops and manufactures equipment for the generation, management, and storage of photovoltaic energy in Spain, Europe and internationally. Positioned at the intersection of technology and energy, the company is pioneering the path to sustainable distributed (power is produced close to where it is consumed) energy future that demands a multifaceted approach. 

Turbo Energy’s product portfolio includes lithium-ion (Li-ion) batteries, multiple models of inverters, software system, and its new all-in-one Sunbox that combines all the components necessary to operate and protect a PV installation.

The company is one of the leaders that introduced Li-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.

In communication with the inverter, Turbo Energy’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which incorporates AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Not Just Energy. More Energy, Better Managed.

The future of energy is undoubtedly tech driven. PV has long been heralded for its potential and is the best understood sustainable energy by consumers. Yet, it has been critiqued for certain limitations, obstacles that companies like Turbo Energy are overcoming today. Advancements in photovoltaics offer a path towards a sustainable future powered by the sun. Companies like Turbo Energy S.A., with their focus on cleantech and energy solutions, have the potential to play a role in this revolution. As technology continues to evolve and solar energy becomes more efficient and cost-effective, we can expect a paradigm shift in how we generate, manage, and consume energy, paving the way for a cleaner and more sustainable future.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• Sigyn Therapeutics CEO Jim Joyce reviewed the company’s pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States
• The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies
• Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively
• To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause the death of healthy patient cells

Sigyn Therapeutics (OTCQB: SIGY), a San Diego-headquartered medical technology company that creates medical solutions to treat life-threatening conditions, took part in the recent Emerging Growth Conference, with CEO Jim Joyce giving a live online presentation and updating attendees on the company’s portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare (https://ibn.fm/HSNBl).

“We have two classes of product candidates. The first are devices to treat pathogen-associated disorders that are beyond the reach of drugs, and then we have a series of devices designed to improve patient responses to cancer therapies. The convergence of medical devices to enhance cancer drug therapies has the potential to be a new product category,” introduced Mr. Joyce.

Sigyn Therapy(TM)

As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through product development and subsequently completed five invitro blood purification studies, which validated the ability of Sigyn Therapy(TM) to extract 12 different therapeutic targets from human blood plasma.  As a result of these study outcomes, Sigyn Therapy(TM) is a candidate to treat a wide range of pathogen-associated disorders that are not addressed with drug therapies. The company also completed animal studies at the University of Michigan and then collaborated with a leading dialysis organization to establish the treatment protocol, site locations, and principal investigators for first-in-human studies of Sigyn Therapy(TM).

As indicated by Mr. Joyce, “We believe Sigyn Therapy has an unprecedented capability to simultaneously clear deadly inflammatory mediators and pathogenic sources of life-threatening inflammation from human blood.”

Sigyn Therapeutics is preparing to initiate first in-human studies of Sigyn Therapy, having drafted an Investigational Device Exemption (“IDE”) for submission to the U.S. Food and Drug Administration (“FDA”). The study intends to demonstrate the safety of Sigyn Therapy(TM) in dialysis-dependent end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation. “As per our protocol, we plan to enroll a total of 12 to 15 ESRD patients at three site locations,” he conveyed.

Mr. Joyce went on to discuss the potential value of Sigyn Therapy to the dialysis industry as well as non-dialysis markets. Designed as a single-use disposable device that is deployable on dialysis machines, Sigyn Therapy could provide dialysis organizations such as Fresenius Medical Care and DaVita Inc., a strategy to improve the health of their current patient population as well as a potential pathway into non-dialysis markets.

Solutions to Improve Patient Response to Cancer Therapies

Sigyn Therapeutics is also developing devices to improve patient responses to chemotherapy and immunotherapeutic antibodies to treat cancer.

“Something you need to know – something you probably don’t know – is that both chemotherapy and immunotherapeutic antibodies are poorly delivered to their intended cancer targets,” explained Mr. Joyce. “In general, published reports would indicate that less than 2% of chemotherapy and immunotherapeutic antibodies are successfully delivered to their targets. So, consider that no more than $200 of a $10,000 drug dose is likely to provide patient benefit.  We are looking to overcome the delivery limitations of these drugs.”

Against this backdrop, Sigyn Therapeutics is focused on enhancing the performance of cancer drugs. “We have designed devices to optimize the delivery of chemotherapy and therapeutic antibodies. And we do this by extracting circulating decoys that sequester or interfere with the delivery of these drugs to intended cancer targets. Our clinical objective is straightforward: improve drug delivery, reduce toxicity, and extend patient life,” he continued.

The company has developed ChemoPrep and ImmunePrep, which are designed to enhance the delivery of chemotherapy and therapeutic antibodies, respectively. “ChemoPrep is administered prior to chemotherapy infusion to sweep tumor-derived exosomes and other drug blocking agents from the bloodstream prior to the subsequent administration of chemotherapy.”

To reduce toxicity, the company is developing ChemoPure to be administered after the delivery of chemotherapy to sweep off-target chemotherapy from the bloodstream before it is able to cause the death of healthy patient cells.

In discussing ImmunePrep, Mr. Joyce overviewed the immense opportunities in the therapeutics antibodies market, noting that immunotherapeutic antibodies represent nine of the top 15 selling cancer drugs and have been at the center of multi-billion-dollar mergers and acquisitions. “When we reference immunotherapeutic antibodies, I just want you to know this is inclusive of monoclonal antibodies, checkpoint inhibitors, and antibody drug conjugates. There are over 1000 antibodies right now being evaluated in human studies. However, there is no therapy that’s been proposed prior to ImmunePrep to address the drug decoys that inhibit the delivery of these drugs,” he continued.

Unlike ChemoPrep, ImmunePrep establishes a platform for therapeutic antibodies to be incorporated within medical devices to sweep drug decoys from the bloodstream that would intercept the delivery of the same therapeutic antibody when subsequently administered. The company believes this reverse decoy mechanism will increase the availability of infused antibodies to bind their intended therapeutic target.  Simultaneously, the ImmunePrep device is designed to extract intended cancer cells targets of the antibody from the bloodstream to provide further benefit without added drug toxicity.

Mr. Joyce also fielded questions, using this opportunity to compare the Sigyn Therapy with other blood purification technologies that treat pathogen-associated conditions as well as discuss the company’s potential revenue verticals, funding outlook, development timelines, and potential opportunities to collaborate with medical device and biopharmaceutical organizations.

To listen to the full presentation, please visit https://ibn.fm/7AuwX.

For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

• Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update
• The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart
• Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024
• The company also reported that it is exploring opportunities to advance its Alzheimer’s disease program through potential partnerships or other sources of funding

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year.

“In 2023 we made significant strides advancing studies of our investigational product, Lomecel-B(TM), in Hypoplastic Left Heart Syndrome (“HLHS”) and Alzheimer’s disease, with long-term survival data from ELPIS I trial presented at the American Heart Association (‘AHA’) annual meeting and clinically meaningful results announced from our Phase 2a CLEAR MIND clinical trial of Lomecel-B(TM) in the treatment of mild Alzheimer’s disease,” said Longeveron CEO Wa’el Hashad.

The ELPIS I trial was an open-label Phase 1 study designed to investigate the safety and potential efficacy of the intramyocardial injection of Lomecel-B(TM) administered to 10 infants with HLHS during the Glenn procedure, the second of three open-heart surgeries performed to correct HLHS, at about 4-5 months of age. (HLHS is a congenital condition characterized by the underdevelopment of the left side of the heart.) The final results from the study, announced in September 2021, showed that the study met its primary safety endpoint and that all patients were alive, transplant-free, and maintained their expected rate of growth one year after treatment (https://ibn.fm/nTsZs).

Nonetheless, after ELPIS I came to its planned end, investigators elected to extend the follow-up of the 10 infants for a total period of five years. It is the data from this ongoing extended long-term follow-up that the company presented as a poster at the 2023 annual AHA meeting. The company also summarized this data in its recent corporate update, noting that children in the ELPIS I trial had 100% transplant-free survival up to five years of age after receiving Lomecel-B(TM) compared to about 20% mortality rate observed from historical control data. This data, the update continued, reinforces the potential survival benefit of Lomecel-B(TM) for patients with HLHS.

The update also emphasized Longeveron’s prioritization of the development of Lomecel-B(TM) in HLHS. “For 2024 our main strategic priority will be focused on our lead clinical program in HLHS, our most important near-term value driver. Accordingly, we made the strategic decision to discontinue our Phase 2 clinical program in Aging-related Frailty in Japan,” explained Hashad.

The company is expecting to complete enrollment in the ELPIS II trial, a Phase 2 controlled clinical trial, in the fourth quarter of calendar 2024. (The company announced in August last year that it had surpassed 50% enrollment threshold) (https://ibn.fm/eBxKN). To achieve this target, Longeveron plans to implement additional measures that the company’s management outlined during the conference call that accompanied the release of the financial results (https://ibn.fm/vVij1).

For instance, Longeveron is in the process of activating new sites to add to its existing seven sites. Additionally, the company is working with advocacy groups to increase awareness among patients and is planning to hold an investigator meeting during which the company intends to take additional measure with the goal of expediting study enrollment.

“We are also exploring opportunities to advance our Alzheimer’s disease program through potential partnerships or other sources of funding. These steps will allow us to focus our available resources on completing enrollment in our follow-on ELPIS II study in 2024. HLHS patients are in critical need of new therapeutic options to improve outcomes in this rare and life-threatening indication,” Hashad continued.

Longeveron’s focus on its Alzheimer’s disease program comes on the back of positive results from the Phase 2a CLEAR MIND trial of Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. According to the corporate update, the study met its primary safety and secondary endpoints. These results, Longeveron stated, support the therapeutic potential of Lomecel-B(TM) in treating mild Alzheimer’s disease and provide evidence-based support for potential further clinical development.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

• The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion
• The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029.
• Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost the profitable yield of hemp and cannabis production

The United States has seen a rising awareness of the health and therapeutic benefits of cannabinoids, prompting an expected market increase of 15.3%, from $22.23 billion in 2023 to an anticipated $60.36 billion by 2030 (https://ibn.fm/xyDpO). Focused on optimizing and improving higher yields, Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, and its wholly-owned subsidiary AgLAB Inc., have developed a mass spectrometer designed for use in the hemp and cannabis market.

During the process of converting cannabis biomass into distillate, valuable cannabinoids are typically lost resulting in reduced profits. AgLAB’s Maximum Value Processing (“MVP”) Method that uses the powerful AgLAB-1000-D2 mass spectrometer to test and to accurately configure the distillation system for optimal efficiency.

The AgLAB MVP mass spectrometer and its rugged design is built to withstand the demands of the factory floor. The AgLAB-1000-D2 model offers real-time potency tests during each distillation batch cycle.  During the distillation process up to 20 tests per hour can be achieved providing almost instant, real-time results which is used to adjust parameters, such as temperature, feed rate, and vacuum, to optimize potency and increase yields for each batch. Currently testing results can take days to complete resulting in little intelligence towards processing efficiency.

“This product and method fill a void by providing an easy and accurate real-time analysis that is used to make the right adjustments and improve the yields,” an AgLAB employee, was quoted as saying in a press release about AgLAB’s 1000 series (https://ibn.fm/kD3IM).

AgLAB’s method has been extensively tested and has shown impressive results, including increased revenue and profit margins. Internal studies have shown an average revenue improvement of $5,000 per 200 kg of crude, with a 24% profit increase. Furthermore, a case study revealed a 32.9% increase in distillate mass, translating to significant weekly and annual revenue gains.

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

• Video streaming is expected to reach a market size of $279.5 million in 2024 and grow to $1.3 billion by 2034 due to the demand for live-streamed content and technology advancements
• Immersive content is in high demand – blending lifestyle content with entertainment elements, often through apps supporting Video-On-Demand content and traditional broadcast television
• Bravo’s acquisition of Streaming TVee’s assets further the company’s goal of advancing its video streaming and entertainment ventures with a beta launch of its TVee NOW(TM) streaming service in Q1 2024

The video streaming market is expected to keep growing in the coming years. It is estimated to grow from $279.5 million in 2024 to $1.3 billion by 2034, growing at a CAGR of 16.4%. The market’s substantial growth is due to an increased demand for live-streaming content and technological advancements that propel the expansion of the market (https://ibn.fm/Bopwf). Bravo Multinational (OTC: BRVO), a company focused on exploring opportunities in the entertainment, hospitality, and technology sectors to generate long-term value for its shareholders through high-growth business ventures, is focused on advancing video streaming and its entertainment ventures.

The key to capturing an audience’s attention in entertainment lies in delivering outstanding content and immersive experiences that seamlessly blend lifestyle and entertainment elements. Content creators can forge deeper connections with audiences and leave lasting impressions by using their expertise across various domains, including television, film, music production, live events, immersive attractions, culinary experiences, retail products, and gaming.

One of the fundamental aspects of connecting lifestyle and entertainment is understanding the pulse of the audience. Content creators must delve into their target demographic’s preferences, aspirations, and cultural nuances to craft experiences that resonate on a personal level. Whether through compelling storytelling, innovative visual techniques, or interactive elements, the goal is to transport audiences into a world where they feel fully immersed and engaged.

Television and film serve as powerful mediums for storytelling, offering a canvas for creators to explore a variety of narratives and perspectives. By producing high-quality content that reflects the richness of human experiences, filmmakers can evoke emotions, spark conversations, and inspire change. From gripping dramas to light-hearted comedies, each genre presents an opportunity to delve into different facets of lifestyle while keeping entertainment at the forefront.

Music production and behind-the-scenes content add another dimension to the immersive experience. Whether creating original soundtracks for films, curating playlists for live events, or producing albums that capture the essence of a particular lifestyle, music can evoke emotions and set the tone for memorable moments. By integrating music seamlessly into various entertainment offerings, creators can amplify the overall experience and forge deeper connections with their audience.

In February 2024, Bravo finalized a deal to acquire Streaming TVEE Inc.’s assets, allowing it to establish its flagship offering – TVee NOW(TM). The acquired assets provide the company with the technology and foundation to offer streaming services, including Video-On-Demand (“VOD”) and traditional broadcast television through a joint venture partner.

In the acquisition, Bravo obtained exclusive rights, image and likeness, label waivers, and exploitation rights for streaming 117 high-definition music and comedy performances – offering director’s cuts and multiple camera perspectives. The original content offering will allow Bravo to recreate shows in diverse formats, showcasing concert films in a new full-feature format.

Bravo’s service is set for beta launch in Q1 2024. It will be accessible across various devices, with dedicated apps on platforms like Roku, Apple, and Google Play stores. The offering only reinforces the company’s commitment to innovation and audience accessibility.

For more information, visit the company’s website at www.BravoMultinationalInc.com.

NOTE TO INVESTORS: The latest news and updates relating to BRVO are available in the company’s newsroom at https://ibn.fm/BRVO

• Demand for photovoltaic energy storage systems in the EU is growing, driven by increased demand for energy security, renewable energy sources, and grid stability
• TURB strongly positioned with patented Sunbox – an AI-powered solution for home and business photovoltaic systems
• Sunbox leverages AI-powered algorithms to optimize energy usage, maximize efficiency, and protect against price shocks
• Market size for solar energy storage batteries projected to grow from $4.40 billion in 2023 to $20.01 billion by 2030 at a CAGR of 24.2%

Demand for photovoltaic energy storage systems in the European Union is growing, driven by environmental concerns and the goal of reducing dependence on fossil fuels (https://ibn.fm/dXFtt). The adoption of solar power systems combined with battery storage is driving the surge with an emphasis on energy security, integration of renewable energy sources, and enhanced grid stability.

Turbo Energy (NASDAQ: TURB), a photovoltaic energy company based in Spain, is strongly positioned to capitalize on increased demand with its patented Sunbox – an AI-powered solution for home and commercial photovoltaic installations.

Following the recent acquisition of an international patent, Turbo Energy is now strategically determining the countries for registration. “The result will be a unique energy storage solution that we believe will provide Turbo a leading position in this industry worldwide and help pave the way towards a more sustainable and energy-efficient future,” stated Turbo as they received their Spanish patent (https://ibn.fm/LqEcR).

Sunbox helps EU policymakers meet environmental goals while incentivizing consumers through lowered energy costs, maximized efficiency, and price shock protection. The system provides a comprehensive and intelligent energy management solution, utilizing AI algorithms to optimize energy usage while ensuring a reliable power supply. Additionally, the integration of an electric vehicle charger enables seamless charging at home and increased reliability on the road.

“It is the result of years of work on power inverters’ electronics with the aim of making them more useful for the end consumer,” said Pablo de la Cuadra, Director of Development at TURB.

The projected market size for solar energy storage batteries is anticipated to expand from $4.40 billion in 2023 to $20.01 billion by 2030 at a CAGR of 24.2% over the forecast period (https://ibn.fm/ulfj9). As an industry pioneer, TURB offers next-generation solar energy batteries that leverage proprietary software, offering a competitive advantage in the growing sector. With a focus on the home energy storage market, TURB’s batteries boast capacities ranging from 2.24 kWh to 5.1 kWh in 24 and 48 volts, with the latter option available in a dual battery system.

Turbo Energy was incorporated in 2013 and operates as a subsidiary of Umbrella Solar Investment S.A. in Valencia, Spain. Led by CEO Mariano Soria, the company’s management team leverages decades of experience in renewable energy technology, finance, and sales to drive the company’s strategic vision forward in the growing energy storage market industry.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

Astiva Health Inc. is pioneering transformative healthcare for seniors, with a focus on enhancing mobility and promoting independence. This innovative approach places a strong emphasis on seniors as active participants in their healthcare journey, representing a shift towards a more interactive and preventive model of care.

Embracing Active Participation

Central to Astiva Health’s mission is empowering seniors to engage actively in their healthcare decisions, supporting their flourishing in later years. The CDC highlights physical activity’s crucial role in preventing chronic diseases among seniors, noting that regular physical activity can significantly reduce health risks associated with inactivity (CDC, 2020).

Tailored Exercise Programs for Active Participants

Astiva Health is committed to empowering seniors through customized exercise programs that cater to their unique needs and health goals. The organization facilitates easy access to a variety of activities, including gyms, yoga, and water aerobics. Next year, Astiva will introduce new exercise benefits, enabling members to access additional facilities, fostering an environment where seniors can actively engage in their wellness journey.

Nutritional Support and Healthy Lifestyle Choices

Astiva Health places a strong emphasis on nutritional support, offering a top-of-the-market grocery benefit of currently $100 per month to encourage seniors to choose healthy foods. This initiative ensures that grocery benefits are accessible at local markets where seniors commonly shop, making it easier for them to incorporate nutritious foods into their diet. This approach has seen nearly 100% usage by Astiva’s members, significantly simplifying the process of maintaining a healthy diet compared to other programs that may appear beneficial but are difficult to utilize.

Accessible Transportation: Empowering Mobility

To overcome mobility challenges and encourage active participation in community life, Astiva Health provides accessible transportation solutions. This initiative helps seniors maintain an active social life, access healthcare appointments, and engage in community events, directly combating isolation and promoting inclusivity.

Conclusion

Astiva Health Inc. is redefining senior healthcare by fostering an environment where seniors are recognized as active participants in their health management. Through tailored exercise programs, substantial grocery benefits encouraging healthy eating, and accessible transportation, Astiva Health empowers seniors to lead more active, healthy, and independent lives. As the global population ages, Astiva’s proactive and participatory healthcare solutions become increasingly essential for ensuring seniors can thrive in their golden years.

For more about Astiva Health’s innovative approach to senior healthcare, visit AstivaHealth.com. Astiva is dedicated to offering innovative, culturally responsive Medicare Advantage options tailored to the active lifestyles of modern seniors.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva